Clinical Trial Update: A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label dose-finding trial evaluating CC-122 in combination with ibrutinib and obinutuzumab for chronic lymphocytic leukemia/small lymphocytic lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CC-122
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Celgene | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-20